Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals is a specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, particularly in dermatology and autoimmune conditions, where approved therapies are limited or unavailable. The company's lead program, QRX003, is a topical serine protease inhibitor in pivotal clinical testing for Netherton Syndrome and related ichthyosis disorders, with additional candidates in earlier development stages targeting conditions such as scleroderma and vascular malformations. Quoin plans to self-commercialize QRX003 in the U.S., Western Europe, and Japan through a focused sales model targeting dermatologists, while leveraging commercial partnerships covering 61 additional countries; the company has not yet generated revenue and is pre-commercialization, with financial success dependent on completing clinical development and obtaining regulatory approval.